OnabotulinumtoxinA for Treatment of Moderate-To-Severe Horizontal Lines and Glabellar Lines From the Subject's Perspective: Patient-Reported Satisfaction and Impact Outcomes From a Phase 3 Double-Blind Study
SKIN The Journal of Cutaneous Medicine
doi 10.25251/skin.1.supp.81
Full Text
Open PDFAbstract
Available in full text
Date
October 27, 2017
Authors
Publisher
National Society for Cutaneous Medicine